Immunological signature of patients with thymic epithelial tumors and Good syndrome
Anna Maria Malfitano(University of Naples Federico II), Pietro Formisano(Institute for Experimental Endocrinology and Oncology), Pietro De Placido(University of Naples Federico II), Liliana Montella(Ospedale Santa Maria), Daniela Terracciano(Federico II University Hospital), Marianna Tortora(Regione Campania), Brigitta Mucci(Federico II University Hospital), Vittoria D’Esposito(Institute for Experimental Endocrinology and Oncology), Margaret Ottaviano(University of Naples Federico II), Mario Giuliano(Regione Campania), Sabino De Placido, Fabiana Napolitano(Harold C. Simmons Comprehensive Cancer Center), Rocco Morra(Federico II University Hospital), Erica Pietroluongo(University of Naples Federico II), Giovannella Palmieri(Regione Campania)
Cited by 16
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273